Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088907 · ClinicalTrials.gov registry record · Phase 3
Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 3
- Development phase
- 270
- Enrollment target
NCT00088907: Clinical Trial Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00088907 is a Phase 3 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 270 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00088907, a Phase 3 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 270 participants
- Enrollment target
Study Summary
Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Combining docetaxel with gefitinib may kill more tumor cells. It is not yet known whether docetaxel is more effective with or without gefitinib in treating head and neck cancer. This randomized phase III trial is studying docetaxel and gefitinib to see how well they work compared to docetaxel alone in treating patients with metastatic or locally recurrent head and neck cancer.
Interventions
- OTHER placebo
- DRUG docetaxel
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2004-08 |
| Est. Completion | 2012-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00088907
The ClinicalTrials.gov registry entry for NCT00088907 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00088907 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00088907 about?
NCT00088907 is a clinical study titled "Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer". Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Combining docetaxel with gefitinib may kill more tumor cells. It is no...
What is the current status of trial NCT00088907?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 270 participants. The study started on 2004-08. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00088907?
The interventions under investigation include: placebo (OTHER), docetaxel (DRUG), gefitinib (DRUG).
Who is sponsoring clinical trial NCT00088907?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.